CXS won't go anywhere until trial data from both trials are...

CXS won't go anywhere until trial data from both trials are finalised and handed over to Cephalon.

If the data is not up to scratch then expect the SP to plummet.

If Cephalon like what they see they will take up thier options @ 70c and take the lead over the FDA process with the new dataset. This should result in a rise of the SP.

That's the abridged version...if you do not want to take the risk with the trial data you should sell now.